MK-677 vs CJC-1295 DAC — different mechanisms, similar endpoints

MK-677 hits GHS-R1a chronically, CJC-1295 DAC hits GHRH receptor chronically. Both produce sustained IGF-1 elevation in the 40-80% above baseline range.

The side effect differences are interesting. MK-677 has appetite increase and water retention. DAC has injection site reactions and the pulsatile-vs-tonic question. Practical research considerations probably differ more than the endpoints.